Latest: Page 12
Is Galecto a Winner in the Biotech Industry?
Denmark-based biotechnology company Galecto (GLTO) has been making some progress on developing treatments for diseases such as fibrosis and cancer. Th...
Twilio vs. Oracle: Which Cloud Stock is a Better Buy?
The cloud computing industry has been growing consistently with the increasing need for cloud solutions to facilitate hybrid working models and with c...
Does Evofem Biosciences Deserve a Place in Your Portfolio?
Evofem Biosciences (EVFM) has been taking steps to increase awareness about its FDA-approved product—Phexxi. However, the stock has been losing value...
Should You Buy the Dip in Ocugen?
Ocugen's (OCGN) share price plunged sharply following the company's announcement on June 10 that it will pursue a BLA rather than an EUA for Bharat Bi...
Down 12% Over the Past Month, is Now a Good Time to Scoop Up Gap Stock?
Gap's (GPS) shares have declined 12% over the past month following the company's sale of Janie and Jack and its proposed sale of Intermix. But the company has assured the market that these transactions are part of its Power Plan 2023. So, the question is, given the increasing foot traffic at GPS' retail stores and its strong digital presence, is it wise to buy the dip in the stock? Let's find out.
Is Tesla a Buy Under $600?
Electric vehicle (EV) maker Tesla's (TSLA) shares are currently trading significantly below their $900.40 all-time high, which they hit in January 2021. The price decline can be attributed primarily to the problems TSLA is facing because of a global semiconductor shortage. The question is, given the EV industry's immense growth potential and TSLA's dominant position in the market, is it wise to buy the stock at the current price level? Let's find out.